Table 4.

Differences in QOF CVD prescribing targets^a by serious mental illness status adjusted for sociodemographic characteristics and primary care consultation frequency

	Reference (non-SMI)	Unadjusted OR (95% CI)	Adjusted for sociodemographics ORb (95% CI)	Additionally adjusted for consultation rate ORc (95% CI)
Beta blocker
After CHD	1.00	0.62 (0.41 to 0.93)d	0.68 (0.44 to 1.05)	0.66 (0.42 to 1.01)
After HF	1.00	0.29 (0.16 to 0.53)f	0.29 (0.15 to 0.55)f	0.27 (0.14 to 0.52)f
ACEI/ARB
After CHD	1.00	0.59 (0.36 to 0.97)d	0.55 (0.33 to 0.94)d	0.47 (0.27 to 0.80)e
After HF	1.00	0.33 (0.18 to 0.61)f	0.34 (0.18 to 0.66)f	0.31 (0.16 to 0.60)f
Antiplatelet/anticoagulant
After CHD	1.00	0.95 (0.54 to 1.65)	1.04 (0.57 to 1.89)	0.94 (0.51 to 1.73)
After STIA	1.00	1.04 (0.68 to 1.60)	0.99 (0.62 to 1.59)	1.04 (0.64 to 1.69)
Statin
After CHD	1.00	0.76 (0.45 to 1.28)	0.78 (0.45 to 1.36)	0.70 (0.40 to 1.23)
Quadruple therapyg
After CHD	1.00	0.65 (0.40 to 1.06)	0.62 (0.37 to 1.04)	0.28 (0.34 to 0.98)d

ACEI/ARB = angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. CHD = coronary heart disease. CVD = cardiovascular disease. HF = heart failure. OR = odds ratio. QOF = Quality and Outcomes Framework. SMI = severe mental illness. STIA = stroke/ transient ischaemic attack.

^aRefers to QOF guidelines 2012/13.¹⁷

^bAdjusted for age (continuous), sex, ethnic group, and borough-level deprivation.

^cAdditionally adjusted for mean annual number of primary consultations.

^dP <0.05.

^eP <0.01.

^fP <0.001.

^gQuadruple therapy indicated in patients with history of myocardial infarction and includes statin, antiplatelet/anticoagulant, beta blocker, and ACEI/ARB medication.